End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.485 EUR | +12.53% | -25.38% | -83.28% |
Jul. 10 | Acticor: operations financed through to September | CF |
Jun. 04 | Acticor: hopes revived in stroke, share price rises | CF |
Business Summary
The group has one product in Phase II/III clinical development (Glenzocimab).
Number of employees: 29
Managers
Managers | Title | Age | Since |
---|---|---|---|
Gilles Avenard
FOU | Founder | - | 13-11-25 |
Eric Cohen
DFI | Director of Finance/CFO | - | - |
Chief Tech/Sci/R&D Officer | - | 18-10-31 | |
Aymeric Humblot
ADM | Chief Administrative Officer | - | - |
Sophie Binay
CTO | Chief Tech/Sci/R&D Officer | - | - |
Yannick Plétan
CTO | Chief Tech/Sci/R&D Officer | - | 17-12-19 |
Adeline Meilhoc
PRN | Corporate Officer/Principal | - | 20-02-29 |
Antoine Lebel
PRN | Corporate Officer/Principal | - | - |
James Stearns
PRN | Corporate Officer/Principal | - | - |
Jessica Jami
LAW | General Counsel | - | 19-10-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Gilles Avenard
FOU | Founder | - | 13-11-25 |
Catherine Boule
BRD | Director/Board Member | - | - |
Alain Munoz
CHM | Chairman | 75 | 21-06-14 |
Alain Parthoens
BRD | Director/Board Member | 64 | 18-10-23 |
Rinaldo del Bono
BRD | Director/Board Member | - | - |
Guy Heynen
BRD | Director/Board Member | - | - |
Patricia Zilliox
BRD | Director/Board Member | - | 23-01-25 |
Corporate Officer/Principal | - | 13-10-31 | |
Leila Nicolas
BRD | Director/Board Member | - | - |
Director/Board Member | - | - |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 12,338,781 | 12,338,781 ( 100.00 %) | 0 | 100.00 % |
Company contact information
Acticor Biotech SAS
Wojo Building 82, avenue du Maine
75014, Paris
+33 6 76 23 38 13
http://www.acticor-biotech.comSector
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-83.28% | 8.29M | |
+20.95% | 127B | |
+23.00% | 117B | |
+26.70% | 27.77B | |
-19.75% | 20.44B | |
-14.87% | 16.62B | |
-16.56% | 15.92B | |
+11.19% | 14.74B | |
-46.65% | 14.94B | |
+57.74% | 14.38B |
- Stock Market
- Equities
- ALACT Stock
- Company Acticor Biotech SAS